AstraZeneca EBITDA Margin 2010-2024 | AZN

Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for AstraZeneca (AZN) over the last 10 years. The current EBITDA margin for AstraZeneca as of March 31, 2024 is .
AstraZeneca EBITDA Margin Historical Data
Date TTM Revenue TTM EBITDA EBITDA Margin
2024-03-31 $47.61B $13.90B 29.19%
2023-12-31 $45.81B $13.58B 29.64%
2023-09-30 $45.00B $13.59B 30.21%
2023-06-30 $44.49B $12.94B 29.08%
2023-03-31 $43.84B $11.10B 25.32%
2022-12-31 $44.35B $9.24B 20.83%
2022-09-30 $45.15B $8.56B 18.96%
2022-06-30 $44.04B $7.10B 16.12%
2022-03-31 $41.49B $7.08B 17.07%
2021-12-31 $37.42B $7.59B 20.27%
2021-09-30 $32.82B $7.97B 24.29%
2021-06-30 $29.53B $8.83B 29.90%
2021-03-31 $27.58B $8.94B 32.42%
2020-12-31 $26.62B $8.31B 31.22%
2020-09-30 $25.87B $8.25B 31.88%
2020-06-30 $25.70B $7.75B 30.15%
2020-03-31 $25.25B $6.97B 27.62%
2019-12-31 $24.38B $6.69B 27.42%
2019-09-30 $24.14B $7.21B 29.85%
2019-06-30 $23.07B $7.28B 31.56%
2019-03-31 $22.40B $7.51B 33.51%
2018-12-31 $22.09B $7.14B 32.32%
2018-09-30 $21.45B $6.19B 28.88%
2018-06-30 $22.34B $6.45B 28.86%
2018-03-31 $22.24B $6.54B 29.42%
2017-12-31 $22.47B $6.71B 29.88%
2017-09-30 $22.27B $8.04B 36.11%
2017-06-30 $21.74B $7.88B 36.24%
2017-03-31 $22.29B $7.23B 32.42%
2016-12-31 $23.00B $7.26B 31.56%
2016-09-30 $23.82B $5.94B 24.94%
2016-06-30 $24.06B $6.04B 25.11%
2016-03-31 $24.77B $6.79B 27.42%
2015-12-31 $24.71B $6.97B 28.19%
2015-09-30 $25.03B $5.83B 23.31%
2015-06-30 $25.69B $5.49B 21.35%
2015-03-31 $26.14B $5.65B 21.62%
2014-12-31 $26.55B $5.42B 20.41%
2014-09-30 $26.77B $6.76B 25.26%
2014-06-30 $26.41B $7.46B 28.26%
2014-03-31 $25.88B $7.80B 30.12%
2013-12-31 $25.81B $8.30B 32.14%
2013-09-30 $26.15B $9.01B 34.45%
2013-06-30 $26.58B $9.82B 36.93%
2013-03-31 $27.01B $10.06B 37.23%
2012-12-31 $27.97B $10.67B 38.13%
2012-09-30 $29.35B $11.08B 37.74%
2012-06-30 $30.88B $12.98B 42.03%
2012-03-31 $32.65B $14.08B 43.12%
2011-12-31 $33.59B $15.35B 45.68%
2011-09-30 $33.55B $16.34B 48.71%
2011-06-30 $33.24B $14.55B 43.77%
2011-03-31 $32.99B $14.37B 43.57%
2010-12-31 $33.27B $14.24B 42.79%
2010-09-30 $33.60B $13.84B 41.19%
2010-06-30 $33.90B $14.44B 42.59%
2010-03-31 $33.68B $14.14B 41.98%
2009-12-31 $32.80B $13.63B 41.55%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $243.139B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Sanofi (SNY) $119.456B 11.27
Innoviva (INVA) United States $1.013B 7.11